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Abstract
Background: Murine breast cancer models relying on intraductal tumor cell inoculations are attractive because they
allow the study of breast cancer from early ductal carcinoma in situ to metastasis. Using a fully immunocompetent 4T1-
based intraductal model for triple-negative breast cancer (TNBC) we aimed to investigate the immunological responses
that guide such intraductal tumor progression, focusing on the prominent role of macrophages.
Methods: Intraductal inoculations were performed in lactating female mice with luciferase-expressing 4T1 mammary
tumor cells either with or without additional RAW264.7 macrophages, mimicking basal versus increased macrophage-
tumor cell interactions in the ductal environment. Imaging of 4T1-derived luminescence was used to monitor primary
tumor growth and metastases. Tumor proliferation, hypoxia, disruption of the ductal architecture and tumor immune
populations were determined immunohistochemically. M1- (pro-inflammatory) and M2-related (anti-inflammatory)
cytokine levels were determined by Luminex assays and ELISA to investigate the activation state of the macrophage
inoculum. Levels of the metastatic proteins matrix metalloproteinase 9 (MMP-9) and vascular endothelial growth factor
(VEGF) as well as of the immune-related disease biomarkers chitinase 3-like 1 (CHI3L1) and lipocalin 2 (LCN2) were
measured by ELISA to evaluate disease progression at the protein level.
Results: Mice intraductally co-injected with macrophages showed severe splenomegaly with faster ductal breakthrough
of tumor cells and increased metastases in axillary lymph nodes and lungs. These mice showed higher M1-related
cytokines in the early disease stages (at 1 to 3 weeks post-inoculation) due to the pro-inflammatory nature of RAW264.7
macrophages with increased Ly6G-positive neutrophils and decreased anti-inflammatory macrophages in the tumor
microenvironment. However, upon metastasis (at 5 weeks post-inoculation), a prominent increase in M2-related cytokine
levels was detected and established a tumor microenvironment with similar immune populations and cytokine responses
as in mice which received only 4T1 tumor cells. The observed tumor-associated immune responses and the increased
metastasis were associated with significantly induced local and systemic levels of MMP-9, VEGF, CHI3L1 and LCN2.
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Conclusions: The current experimental study with an innovative immunocompetent intraductal model for
TNBC pinpoints towards a metastasis-supporting M1 to M2 macrophage polarization in the mammary ducts
mediated by 4T1-derived signaling. We propose to explore this process as immunotherapeutic target.
Keywords: Triple-negative breast cancer, Intraductal model, 4T1 mammary tumor cells, RAW264.7
macrophages, Chitinase 3-like 1, Lipocalin 2
Background
Breast cancer is one of the most prevalent cancers in
women and especially the aggressive subtypes, including
triple-negative breast cancer (TNBC), remain difficult to
treat with traditional chemotherapeutics directly target-
ing the tumor cells [1]. As an alternative treatment,
novel immunotherapeutic strategies now focus on tar-
geting the stromal components in the breast tumor
microenvironment [2, 3]. However, testing of these
promising therapies as well as identification of druggable
immune targets relies on preclinical mouse models that
faithfully mimic breast tumor immunology and tumor
progression [4, 5]. We recently introduced an innovative
mouse model for TNBC that relies on the inoculation of
syngeneic 4T1 murine mammary tumor cells through
the teat canal directly into the mammary ducts (i.e. the
luminal mammary gland compartment) of immunocom-
petent and lactating BALB/c mice, recapitulating the early
ductal carcinoma in situ (DCIS) stage at its onset. Upon
comparison to classical fat pad tumors, intraductal tumors
showed a slower development, yet metastasized at a simi-
lar rate in the presence of potent tumor-associated im-
mune responses [6].
In the current study, we aimed to investigate the im-
mune responses in this innovative intraductal screening
model mediated by macrophage-tumor cell interactions.
Macrophages are the most common innate immune
cells in the breast tumor microenvironment and are
now recognized to act as regulators in multiple breast
cancer-associated processes based on their phenotype
(either M1 or M2) [7–11]. Tumor-associated macro-
phages (TAM) are characterized as a M2 macrophage
population producing key mediators such as matrix
metalloproteinases (including MMP-9) and vascular
endothelial growth factor (VEGF) that stimulate break-
down of the extracellular matrix (promoting tumor cell
invasion) and angiogenesis (promoting tumor cell sur-
vival and metastasis), respectively [7, 8]. Moreover, in
contrast to M1 macrophages that have antitumoral
capacities, M2 macrophages lack tumoricidal (pro-in-
flammatory) activity and exert anti-inflammatory im-
mune responses which prevent the host of mounting an
effective counterattack against the tumor and thereby
stimulate tumor growth and metastasis [7, 8]. By intra-
ductally inoculating 4T1 mammary tumor cells with or
without RAW264.7 macrophages, we verified that the
presence of these latter macrophages in the ductal en-
vironment stimulates 4T1 ductal breakthrough, metas-
tasis and splenomegaly. Investigating the education of
macrophages by mammary tumor cells, we showed
that the increased metastasis in 4T1 and RAW264.7
co-inoculated mice is associated with a shift from
high pro- to anti-inflammatory cytokine levels, indica-
tive for a M1 to M2 macrophage polarization. This prome-
tastatic event is also corroborated by local and systemic
MMP-9 and VEGF levels. Furthermore, local and systemic
levels of CHI3L1 and LCN2, two immune-related bio-
markers used for prognosticating and monitoring disease in
breast cancer patients and mice [6, 12–14], provided an
additional verification of the tumor progression in 4T1 in-
oculated mice with and without RAW264.7 macrophages.
Taken together, this study investigated the effects of
additional macrophages and their polarization on ductal
tumor cell breakthrough and metastasis using a 4T1-based
intraductal model to define novel avenues for the
clinical translation of immunomodulatory applications
against TNBC.
Methods
Animals
Female BALB/c mice were bred, housed and fed ad
libitum in a controlled facility with a light/dark cycle
of 12 h. All research involving animals was performed
in accordance with the recommendations in the Guide for
the Care and Use of Laboratory Animals of the National
Institutes of Health. The study protocols were approved
by the Committee on the Ethics of Animal Experiments of
The Faculty of Veterinary Medicine at Ghent University
(approval number: EC2015/127).
4T1 and RAW264.7 cell culture
The BALB/c-derived 4T1 mammary tumor cell line
used in this study constitutively expresses the firefly lu-
ciferase gene and was a kind gift from Prof. Clare
Isacke (Breakthrough Breast Cancer Research Centre,
London, UK). This tumor cell line resembles the ag-
gressive phenotype and metastasis seen in human
TNBC (estrogen receptor (ER)-negative, progesterone
receptor (PR)-negative and human epidermal growth
factor receptor 2 (HER2)-negative) [15, 16]. The BALB/
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c-derived RAW264.7 macrophage cell line was a kind
gift from Prof. Rudi Beyaert (Unit of Molecular Signal
Transduction in Inflammation, Inflammation Research
Center, Ghent University-VIB, Ghent, Belgium). Both
cell lines were maintained in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 100 U/ml
penicillin and 100 μg/ml streptomycin (Thermo Fisher
Scientific, Waltham, MA, USA) in culture flasks. Har-
vesting of cultured 4T1 cells was performed using
0.25% trypsin- ethylenediaminetetraacetic acid (EDTA)
(Thermo Fisher Scientific), whereas RAW264.7 macro-
phages were harvested using a cell scraper. The harvested
cells were subsequently washed through centrifugation
(805 g for 5 min) and the cell pellets were resuspended
in phosphate buffered saline (PBS). Cell numbers were
determined through counting using a Bürker chamber.
For preliminary in vitro experiments, 4T1 mammary
tumor cells and RAW264.7 macrophages were cultured
either alone (5 × 105 cells in mono-culture) or together
(5 × 105 of each cell type in co-culture) supplemented
with 1 ml of cell culture medium per well in 24 well
plates. The cell cultures were incubated (37 °C, 5% CO2)
for 24 h (to examine CHI3L1 and LCN2 secretion) or
96 h (to examine RAW264.7 macrophage polarization)
with daily change of the cell culture medium. The har-
vested cell culture media were spun down (17,000 g)
for 10 min to remove cellular debris for further ana-
lyses. Cells from 3 wells of 96 h RAW264.7 mono- and
4T1 + RAW264.7 co-cultures were harvested using a
cell scraper, pooled and washed through centrifugation
(805 g for 5 min) for subsequent flow cytometric
analysis.
Flow cytometric analysis of RAW264.7 macrophage
polarization
Harvested and pelleted cells from RAW264.7 mono-
and 4T1 + RAW264.7 co-cultures were suspended in
2.5 ml FACS buffer (containing PBS, 1% bovine serum
albumin (BSA), 2.5 mM EDTA and 0.01% sodium
azide) and 100 μl of the cell suspension was plated in a
well of a 96 well plate for counting through flow cytom-
etry (Analis, Cytoflex). Propidium iodide (PI, 2 μl at
50 μg/ml) was also added to the well to evaluate the
viability of the cells. Remaining cell suspensions were
plated at 100 μl per well in a 96 well plate and the well
plate was centrifuged to pellet the cells (805 g for
5 min). To block Fc receptors found on the RAW264.7
macrophages, cell pellets were subsequently resus-
pended in FcR blocking reagent (1:10 diluted in FACS
buffer; Miltenyi Biotec, Leiden, Netherlands) and incu-
bated for 10 min at 2–8 °C. Following centrifugation,
cell pellets derived from 4T1 + RAW264.7 co-cultures
were stained for 30 min at 2–8 °C with APC-labeled
anti-F4/80 (diluted 1:20 in FACS buffer; clone CI:A3–1;
Bio-Rad, CA, USA) to distinguish RAW264.7 macro-
phages from 4T1 tumor cells. This staining was not per-
formed on cells derived from RAW264.7 mono-cultures as
no distinction is needed between RAW264.7 macrophages
and 4T1 tumor cells. To allow intracellular staining, the
pelleted cells were fixed using BD Cytofix/Cytoperm
solution (Becton Dickinson, Erembodegem, Belgium) for
20 min at 2–8 °C and permeabilized afterwards by washing
twice in 1× BD Perm/Wash Buffer (Becton Dickinson).
Cell pellets derived from RAW264.7 mono- and 4T1 +
RAW264.7 co-cultures were stained for 30 min at 2–8 °C
with PE-labeled anti-IL-12 (diluted 1:20 in 1× BD Perm/
Wash Buffer; clone B211220; BioLegend, CA, USA) or
anti-TGF-β1 (diluted 1:40 in 1× BD Perm/Wash Buffer;
clone TW7-16B4; BioLegend). Istoype-matched and auto-
fluorescence controls were also included for analyses.
Following cellular stainings, cell pellets were washed twice
with 1× BD Perm/Wash Buffer prior to analysis with a
flow cytometer. A maximum of 5% overlap with the iso-
type control signal was allowed when setting the gates to
identify positive F4/80, IL-12 and TGF-β1 signals.
Intraductal inoculations with 4T1 and/or RAW264.7 cells
Intraductal inoculations were conducted in the third
mammary gland pair of female lactating BALB/c mice
under inhalation anesthesia (induction: 2–3% isolflurane
supplemented with oxygen (O2); maintenance: 1–1.5%
isoflurane supplemented with O2) in combination with
intraperitoneal (i.p.) administration of buprenorphine
(long-acting analgesic, 10 μg/kg Vetergesic, Patheon UK
Ltd., Swindon, UK). To attain full lactation, female
BALB/c mice of 8–13 weeks (w) were mated with male
BALB/c mice of 10 w and pups were weaned 12–14 days
following delivery. Mice were inoculated through the
mammary teat canal 1 h after weaning using a 32-gauge
blunt needle with either 5 × 104 4T1 cells, 5 × 104
RAW264.7 macrophages or 5 × 104 of both 4T1 cells
and RAW264.7 macrophages, suspended in a 100 μl
mixture of 1:10 PBS and Matrigel® (Corning, Bedford,
MA, USA). All materials used for inoculation were kept
cold to prevent clotting of the Matrigel®.
Analysis of primary tumor and metastasis progression
Intraductally inoculated mice were screened weekly
through in vivo bioluminescence imaging using the IVIS
lumina II system (PerkinElmer, Zaventem, Belgium) to
monitor growth of 4T1 firefly luciferase-expressing
primary tumors. Mice were injected i.p. with 200 μl
D-luciferin suspended in PBS (2 mg/100 μl; Gold Bio-
technology, St. Louis, MO) and approximately 10 min
later images were acquired under inhalation anesthesia
with isoflurane. Metastases were detected through ex vivo
bioluminescence imaging, which required euthanasia of
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the intraductally inoculated mice and subsequent har-
vesting of metastases-bearing organs. Mice were there-
fore sedated by i.p. injection of a mixture of 100 mg/kg
ketamine (Ketamidor, Ecuphar nv/sa, Oostkamp, Belgium)
and 10 mg/kg xylazine (Xylazini Hydrochloridum, Val
d’Hony-Verdifarm, Beringen, Belgium) and then sacrificed
through cervical dislocation. Axillary lymph nodes and
lungs were isolated and screened for 4T1 metastases. Pri-
mary tumors and spleens were also isolated and weighed
upon sacrification. Quantification of the 4T1-derived bio-
luminescent signals calculated by the living image analysis
software 3.2 from in vivo and ex vivo images was per-
formed by dividing the measured total flux with the
selected area.
Histology and immunohistochemistry
Primary tumors, mammary glands, and metastases-bearing
axillary lymph nodes and lungs were isolated upon
sacrifice of the mice, fixed in buffered 3.5% formalde-
hyde for 24 h at room temperature (RT) and embedded
in paraffin wax. Sections (5 μm) were deparaffinized,
hydrated and stained with hematoxylin and eosin
(H&E). Sections were then dehydrated and mounted
with a cover glass for evaluation.
For immunohistochemical stainings, sections of 2–
3 μm were deparaffinized and antigen retrieval was per-
formed with citrate buffer (10 mM tri-sodium citrate
(Santa Cruz Biotechnology, Heidelberg, Germany)),
pH 6, (for Ki67, carbonic anhydrase IX (CAIX), CD45,
Ly6G, CD163, CD8a, CD31, F4/80) or with Tris-EDTA
buffer (10 mM Tris, 1 mM EDTA (Thermo Fisher Scien-
tific)), pH 9, (for cytokeratin 5) both supplemented with
0.05% Tween-20 (Sigma-Aldrich, Bornem, Belgium) at
95 °C under pressure for 30 min using a Decloaking
Chamber NxGen (Biocare Medical, CA, USA). The
slides were allowed to cool down to RT for 30 min, after
which endogenous peroxidase activity was blocked with
3% H2O2 in methanol (for Ki67, CAIX, cytokeratin 5,
CD45, Ly6G, CD163, CD31 and F4/80) or 0.6% H2O2 in
methanol (for CD8a) for 10 min at RT. Serum-free pro-
tein block (Dako, Heverlee, Belgium) was applied for
10 min at RT to block non-specific binding sites. The
slides were subsequently incubated with primary anti-
body diluted in Antibody Diluent (Dako) for 1 h at RT
and secondary antibodies were incubated for 30 min at
RT. Primary antibodies and dilutions used were:
anti-Ki67 (1:50; clone SP6; Thermo Fisher Scientific);
anti-CAIX (1:1000; NB100–417; Novus Biologicals, Lit-
tleton, CO, USA); anti-cytokeratin 5 (1:100; clone
EP1601Y; Abcam, Cambridge, UK); anti-CD45 (1:1000;
clone 30-F11; Thermo Fisher Scientific); anti-Ly6G
(1:1000; clone 1A8; BioLegend); anti-CD163 (1:500;
clone EPR19518; Abcam); anti-CD31 (1:2000; clone
EPR17259; Abcam); anti-F4/80 (1:10; clone CI:A3–1;
Bio-Rad); anti-CD8a (1:50; clone 4SM15; Thermo Fisher
Scientific). Secondary antibodies used were: Rat-on
Mouse HRP-Polymer (Biocare Medical) for CD45, Ly6G,
F4/80 and CD8a; Dako EnVision+ Rabbit (Dako) for
Ki67, CAIX, cytokeratin 5, CD163 and CD31. A 3,3′-di-
aminobenzidine (DAB)-containing buffer (generated by
adding 1 drop of Dako DAB+ chromogen to 1 ml of
Dako DAB+ substrate buffer) was applied for 10 min at
RT, which created a brownish signal that was visualized
as a positive stain on the slide following counterstaining
in hematoxylin for 3–4 min at RT. All rinsing steps in
between the incubation steps were performed by apply-
ing tris-buffered saline (TBS, Biocare Medical) 3 times
for 2 min at RT. All incubation and rinsing steps from
peroxidase activity blocking to DAB chromogen staining
were performed in a closed microscope slide box (hu-
midified with TBS-wetted tissue paper) on an orbital
shaker at 20 rpm. Next to qualitative assessment, differ-
ences in immunohistochemical staining between the in-
oculation groups at each time point were quantitated
with ImageJ through color deconvolution (3 color split)
and automatic counting.
Cytokine profile analysis and measurement of protein levels
Primary tumors, mammary glands, spleens, axillary
lymph nodes and lungs were isolated and homogenized.
The homogenate was subsequently mixed with 300 μl
lysis buffer supplemented with protease inhibitors (1%
Nonidet P-40, 10 mM Tris-HCl at pH 7.4, 200 mM
NaCl, 5 mM EDTA, 10% glycerol, 100 μM phenyl-
methylsulfonyl (PMSF), 1 mM oxidized L-glutathione
(all from Sigma-Aldrich), 0.15 μM aprotinin and
2.1 μM leupeptin (Roche, Mannheim, Germany)). The
suspensions were frozen overnight to allow their lysis
and centrifuged twice at 17,000 g for 1 h at 4 °C the fol-
lowing day to precipitate the pellet. Protein concentra-
tion of the lysates was determined using the Bradford
Protein Assay (BioRad, Hercules, CA) followed by spec-
trophotometrical measurement (Genesys 10S). Lysates
were diluted to a concentration of 5 μg/μl with lysis
buffer for further analysis. Serum was prepared from
cardiac puncture harvested blood that was clotted
through incubation at 37 °C for 1 h and then centri-
fuged at 17,000 g for 1 h at 4 °C.
A selected profile of cytokines (BAFF, G-CSF, IFN-γ,
IL-1β, IL-4, IL-6, IL-10, MCP-1, MIP-2 and TNF-α)
was quantified in lysates (50 μg protein), sera (diluted
1:4 in assay diluent) and culture media (undiluted)
using Luminex Multiplex Assays (ProcartaPlex from
Thermo Fisher Scientific) according to the manufac-
turer’s instructions. TGF-β1, MMP-9, VEGF, CHI3L1
and LCN2 levels were measured in lysates and sera
using enzyme-linked immunosorbent assay (ELISA) ac-
cording to the manufacturer’s instructions (TGF-β1:
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Mouse uncoated ELISA Kit, Thermo Fisher Scientific;
MMP-9, VEGF, CHI3L1 and LCN2: Mouse Quantikine
ELISA Kit, Biotechne, Minneapolis, MN, USA). A mi-
croplate reader was used to measure the absorbance at
450 nm and 550 nm. Readings at 550 nm were sub-
tracted from those at 450 nm for correction purposes.
A standard curve from recombinant mouse protein was
constructed according to the manufacturer’s instruc-
tions to determine protein levels from the corrected
optical densities using Deltasoft.
Western blot analysis of local CD163 expression
Primary tumor and mammary gland lysates were
equally loaded at a concentration of 20 μg protein per
lane on a 12% polyacrylamide gel (GE Healthcare,
Buckinghamshire, UK). Proteins were separated and
transferred to a 0.45 μm nitrocellulose membrane
(Bio-Rad). The membrane was incubated for 1 h at RT
with blocking buffer (TBS supplemented with 0.1%
Tween-20 and 5% non-fat dry milk) and subsequently
with a primary rabbit anti-mouse CD163 monoclonal
antibody (clone EPR19518, Abcam, diluted 1:1000 in
blocking buffer) overnight at 4 °C. The membrane was
then washed 3 times (5 min for each step) at RT with
blocking buffer and incubated with a secondary donkey
anti-rabbit IgG horseradish peroxidase (HRP) conju-
gated polyclonal antibody (Thermo Fisher Scientific, di-
luted 1:100,000 in blocking buffer) for 1 h at RT. The
membrane was again washed 3 times (5 min for each
step) at RT with blocking buffer and 1 time with des-
tilled H2O (5 min) at RT before detection of the protein
bands. For loading control, the membrane was incubated
overnight at 4 °C with a primary rabbit anti-mouse glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) monoclonal
antibody (clone EPR16891, Abcam, diluted 1:5000 in block-
ing buffer). Donkey anti-rabbit IgG HRP-conjugated
polyclonal antibody (Thermo Fisher Scientific, diluted
1:2000 in blocking buffer) was used as secondary anti-
body to detect the protein bands. Visualization of the
protein bands was performed on a ChemiDoc MP
Imaging System (Bio-Rad) using a SuperSignal West
Femto Kit (Thermo Fisher Scientific). All incubation
steps were performed on a shaking platform. Preci-
sion Plus Protein Dual Color Standards (Bio-Rad)
were loaded on the blot to identify the molecular
weight of the CD163 and GAPDH protein bands.
Quantitative analyses were performed with ImageJ.
Statistical analyses
Statistical analyses were performed using SPSS Statistics
23 (IBM Analytics) and Prism (GraphPad). Data were
checked for normality and, if necessary, log10 transform-
ation was performed to normalize the data. Analysis of
Variance (ANOVA) tests (with Tukey and Tamhane’s T2
post-hoc tests) and unpaired Student’s t-tests were ap-
plied to calculate p-values and determine whether differ-
ences between inoculation groups were statistically
significant (P < 0.05).
Results
RAW264.7 macrophages increase ductal breakthrough,
metastasis and splenomegaly but do not affect primary
tumor growth of intraductally inoculated 4T1 cells
To investigate the influence of macrophages and the
macrophage-tumor cell crosstalk on primary tumor
growth and ductal breakthrough 4T1 mammary tumor
cells were intraductally inoculated with or without
RAW264.7 macrophages (4T1 + RAW264.7 and 4T1 in-
oculation group, respectively) in lactating immunocom-
petent mice. Compared to 4T1 inoculated mice, the
4T1 + RAW264.7 inoculated mice showed no signifi-
cant difference in primary tumor growth up to 5 w
post-inoculation (p.i.) (Fig. 1a and b). Primary tumor
weight at 3 w p.i. (i.e. when primary tumors were palp-
able, but no distant metastases were detectable) and 5
w p.i. (i.e. when metastases became apparent) in both
the 4T1 and 4T1 + RAW264.7 inoculation group cor-
roborated the similar primary tumor growth kinetics in
both inoculation groups (Fig. 1c). Histology of the primary
tumors at 1, 3 and 5 w p.i. indicated the invasiveness of
the 4T1 cells in the lactating mammary ducts with tumor
cells displaying characteristics of metastasis-preceding
epithelial-to-mesenchymal transition (EMT) at 3 w p.i.
and tumor cell invasion of blood vessels at 5 w p.i.
(Fig. 1d). Ki67 staining qualitatively and quantitatively
confirmed a similar tumor cell proliferation in both inocu-
lation groups at 1, 3 and 5 w p.i. (Fig. 2). Stainings for car-
bonic anhydrase IX (CAIX), an enzyme that is
upregulated in hypoxic tumors [17–19], allowed to inves-
tigate tumor hypoxia and identified a similar progressive
increase in CAIX expression from 1 to 5 w p.i. in primary
tumors from both inoculation groups (Fig. 2). Disruption
of the ductal architecture by the tumor cells was quanti-
tated based on cytokeratin 5 stainings for myoepithelial
cells in primary tumors of 4T1 + RAW264.7 and 4T1 in-
oculated mice. Cytokeratin 5 positivity progressively de-
creased in the primary tumors and was significantly lower
at 3 w p.i. in the 4T1 + RAW264.7 compared to the 4T1
tumors, indicative for enhanced tumor cell breakthrough
in the presence of additional macrophages (Fig. 2). In
order to evaluate distant metastases of 4T1 primary tu-
mors both with and without RAW264.7 macrophage
co-inoculation, the axillary lymph nodes and the lungs -
typically the first sites to be affected by metastatic 4T1
cells - were isolated at 5 w p.i. and screened through ex
vivo bioluminescence imaging. Both sites had traces of
metastases (Fig. 3a). The liver was also isolated and
screened but showed no traces of metastases (data not
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shown). Quantification of the bioluminescent signals iden-
tified increased metastasis in axillary lymph nodes and
lungs of the 4T1 + RAW264.7 inoculation group (mean
signal of 5.022 log10 ± 0.2359 p/s/cm
2 in axillary lymph
nodes and 5.003 log10 ± 0.2957 p/s/cm
2 in lungs) com-
pared to the 4T1 inoculation group (mean signal of 4.331
log10 ± 0.1972 p/s/cm
2 in axillary lymph nodes and 4.097
log10 ± 0.2519 p/s/cm
2 in lungs) (Fig. 3b). Comparative
H&E and Ki67 stainings of axillary lymph node and lung
sections from metastasis-bearing mice in the 4T1 +
RAW264.7 versus 4T1 inoculation group corroborated
the ex vivo bioluminescence imaging results with en-
hanced metastatic tumor burden and tumor cell prolifera-
tion in the 4T1 + RAW264.7 inoculation group (Fig. 3c).
The lung metastatic growth in both inoculation groups
was further characterized immunohistochemically by
staining of the immune cell infiltrates (identified by im-
mune cell markers CD45 (pan-immune cell marker),
Ly6G (neutrophil marker), CD8a (cytotoxic immune cell
marker) and CD163 (anti-inflammatory macrophage
marker)) and vascular structures (identified by the endo-
thelial cell marker CD31) (Additional file 1: Figure S1).
The advancement in primary tumor growth and me-
tastasis was reflected by a progressive splenomegaly in
both inoculation groups. Whereas the spleen weight did
not differ at 3 w p.i. between the 4T1 + RAW264.7 and
4T1 inoculation group, splenomegaly became more pro-
nounced at 5 w p.i. in the 4T1 + RAW264.7 inoculation
group (Fig. 3d and e). Indeed, spleen weights and sizes
at 5 w p.i. were approximately 1.5 times larger in the
4T1 + RAW264.7 inoculation group compared to the
4T1 inoculation group.
Co-inoculation of RAW264.7 macrophages with 4T1
mammary tumor cells mediates a M1 to M2 macrophage
polarization in the mammary tumor microenvironment
Macrophages are known as important immunomodulators
in the breast tumor microenvironment and can strongly
affect disease progression. More specifically, macro-
phages can stimulate either pro- or anti-inflammatory
immune responses based on their activation state, i.e.
either M1 or M2. Flow cytometric analysis identified a
M1 to M2 polarization of RAW264.7 macrophages
co-cultured with 4T1 tumor cells based on their
Fig. 1 Similar primary tumor growth in 4T1 + RAW264.7 versus 4T1 intraductally inoculated mice. Lactating immunocompetent BALB/c mice were
intraductally inoculated in the third mammary gland pair with bioluminescent traceable 4T1 mammary tumor cells either with or without
RAW264.7 macrophages. a Primary tumor growth up to 5 w p.i. based on weekly measurements of the total flux radiance (p/s/cm2) at the
inoculation sites (number of tumors at each time point: 4T1 + RAW264.7 inoculation group: n = 36 at 1 w p.i., n = 32 at 2 w p.i., n = 31 at 3 w p.i.,
n = 18 at 4 w p.i., n = 17 at 5 w p.i.; 4T1 inoculation group: n = 32 at 1 w p.i., n = 28 at 2 w p.i., n = 26 at 3 w p.i., n = 11 at 4 w p.i., n = 16 at 5 w
p.i.). b Representative image of the bioluminescence signal at 5 w p.i. in both inoculation groups. c Measurement of the primary tumor weight at
3 and 5 w p.i. in both inoculation groups (number of tumors: 4T1 + RAW264.7 inoculation group: n = 8 at 3 w p.i., n = 14 at 5 w p.i.; 4T1
inoculation group: n = 8 at 3 w p.i., n = 10 at 5 w p.i.) d H&E histology of 4T1 + RAW264.7 and 4T1 primary tumor tissue at 1, 3 and 5 w p.i. Arrows
indicate tumor cells; asterisks (*) indicate zones in the tumor mass that are characteristic for epithelial-to-mesenchymal transition (EMT). All scale
bars = 50 μm. Data in panel (a) and (c) are presented as the means +/− standard error of the mean (SEM). NS: not significant
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significantly decreased intracellular expression of the
M1-related (i.e. pro-inflammatory) cytokine interleukin
(IL)-12 and significantly increased intracellular expres-
sion of the M2-related (i.e. anti-inflammatory) cytokine
transforming growth factor (TGF)-β1 compared to
RAW264.7 macrophages that were cultured alone
(Fig. 4a). In addition, culture media of 4T1 +
RAW264.7 co-cultures showed significantly decreased
levels of the M1-related cytokine tumor necrosis factor
(TNF)-α and significantly increased levels of the
M2-related cytokines B-cell activating factor (BAFF),
granulocyte colony-stimulating factor (G-CSF) and
TGF-β1 compared to RAW264.7 mono-culture media
(Fig. 4b). To provide more insights into the immuno-
logical impact of the co-inoculated macrophages on the
observed tumor progression in vivo, local and systemic
M1−/M2-related cytokine profiles were investigated
and compared at 3 and 5 w p.i. in the primary tumor
lysates and sera from the 4T1 + RAW264.7 and 4T1 in-
oculation group. At 3 w p.i. 4T1 + RAW264.7 primary
tumor lysates showed a significant increase in the
M1-related cytokines IL-1β, monocyte chemoattractant
protein (MCP)-1, macrophage inflammatory protein
(MIP)-2 and TNF-α compared to the 4T1 primary tu-
mors, whereas the M2-related cytokines BAFF, G-CSF,
IL-4 and TGF-β1 showed significantly lower levels in
the 4T1 + RAW264.7 versus the 4T1 primary tumors
(Fig. 5a and b). However, at 5 w p.i. these differences
in M1- and M2-related cytokine profiles could no
longer be detected between both inoculation groups
(Fig. 5c and d). M1- and M2-related cytokines were also
measured in lysates of RAW264.7 macrophage-only intra-
ductally inoculated mammary glands. These results
showed that the 4T1 tumor cells strongly influence the
local and RAW264.7 macrophage-mediated immune
responses as, compared to 4T1 + RAW264.7 and 4T1
primary tumors, RAW264.7-only mammary glands con-
tained higher M1-related cytokine levels (interferon
(IFN)-γ, IL-1β and TNF-α at 3 and 5 w p.i., and MCP-1
and IL-6 at 5 w p.i. compared to 4T1 + RAW264.7 and
4T1; MCP-1 and MIP-2 at 3 w p.i. compared to 4T1) and
lower M2-related cytokine levels (BAFF and IL-4 at 3 and
5 w p.i., IL-10 at 3 w p.i., and TGF-β1 at 5 w p.i. compared
to 4T1 + RAW264.7 and 4T1; G-CSF and TGF-β1 at 3 w
p.i. compared to 4T1; G-CSF at 5 w p.i. compared to 4T1
+ RAW264.7) (Fig. 5).
In contrast to the local primary tumor the serum
cytokine levels were far less different between the
4T1 + RAW264.7 and 4T1 inoculation group at 3 and
5 w p.i. More specifically, at 3 w p.i. the serum levels
of the M1-related cytokine MCP-1 were higher and
the M2-related TGF-β1 serum levels were lower in
the 4T1 + RAW264.7 compared to the 4T1-only in-
oculation group (Additional file 2: Figure S2A and B).
Fig. 2 Similar cell proliferation and hypoxia, but differential ductal breakthrough in primary tumors of 4T1 + RAW264.7 versus 4T1 intraductally
inoculated mice. Immunohistochemistry for the cell proliferation marker Ki67, hypoxia-associated enzyme carbonic anhydrase IX (CAIX) and
myoepithelial cell marker cytokeratin 5 was performed on paraffin sections of primary tumors at 1, 3 and 5 w p.i. from 4T1 + RAW264.7 and 4T1
inoculated mice. The percentage of Ki67-, CAIX- and cytokeratin 5-positive staining was quantified (n = 5 at each time point and for each
inoculation group). Scale bars = 50 μm. All data are presented as the means +/− SEM. NS: not significant, ***: P < 0.001
Steenbrugge et al. Journal of Experimental & Clinical Cancer Research  (2018) 37:191 Page 7 of 18
Fig. 3 (See legend on next page.)
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Fig. 3 Differential metastasis and splenomegaly in 4T1 + RAW264.7 versus 4T1 intraductally inoculated mice. a Representative image of the ex
vivo bioluminescence imaging of 4T1 metastases in isolated axillary lymph nodes and lungs at 5 w p.i. b Quantification of 4T1-derived
bioluminescence signals (in p/s/cm2) in the axillary lymph nodes and lungs of 4T1 + RAW264.7 and 4T1 inoculated mice (4T1 + RAW264.7
inoculation group: n = 7 axillary lymph nodes, n = 8 lungs; 4T1 inoculation group: n = 8 axillary lymph nodes, n = 7 lungs). c H&E histology and
Ki67 immunohistochemistry of axillary lymph node and lung metastases in 4T1 + RAW264.7 and 4T1 inoculated mice at 5 w p.i. White dashed
lines and black arrows indicate tumor-rich regions. The detailed image of Ki67 staining in the axillary lymph nodes identifies the border between
normal lymph node tissue (N) and tumor-rich tissue (T). The bar graphs show the percentage of Ki67-positive staining in the axillary lymph node
and lung metastases from 4T1 + RAW264.7 and 4T1 inoculated mice (n = 5 axillary lymph nodes and n = 3 lungs for each inoculation group).
Black scale bars = 200 μm, green scale bars = 100 μm, red scale bars = 50 μm. d Weight measurement of spleens isolated at 3 and 5 w p.i. from
4T1 + RAW264.7 and 4T1 inoculated mice (number of spleens: 4T1 + RAW264.7 inoculation group: n = 5 at 3 w p.i., n = 7 at 5 w p.i.; 4T1
inoculation group: n = 5 at 3 w p.i., n = 6 at 5 w p.i.). e Representative images of isolated spleens at 5 w p.i. from 4T1 + RAW264.7 and 4T1
inoculated mice. The image of an isolated spleen from a non-inoculated mouse is also shown for comparative purposes. Data in panel (b), (c)
and (d) are presented as the means +/− SEM. NS: not significant, *: P < 0.05
Fig. 4 M1 to M2 polarization upon co-culturing of RAW264.7 macrophages with 4T1 tumor cells. a Flow cytometric analysis for intracellular
expression of the pro-inflammatory/M1-related cytokine IL-12 and anti-inflammatory/M2-related cytokine TGF-β1 in RAW264.7 macrophages after
96 h mono-culture and co-culture with 4T1 tumor cells (n = 3 for all culture conditions). RAW264.7 macrophages derived from 4T1 + RAW264.7
co-cultures were gated (purple) based on positivity for F4/80 (green line) relative to the isotype control (blue line). The gates for IL-12 and TGF-β1
(purple) were applied for quantification of both positive signals (red line) relative to their isotype control signal (blue line). The bar graphs show
the percentage of the F4/80-positive cells based on the applied gatings. b Levels of secreted pro-inflammatory/M1-related (TNF-α) and anti-
inflammatory/M2-related (BAFF, G-CSF and TGF-β1) cytokines in cell-free culture media of 24 h mono- and co-cultures of RAW264.7 macrophages
and 4T1 mammary tumor cells (n = 3 for all culture conditions). All data are presented as the means +/− SEM. ND: not detectable, *: P < 0.05, **:
P < 0.01, ***: P < 0.001
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These systemic differences were no longer detected at
5 w p.i. (Additional file 2: Figure S2C and D). In con-
trast to tumor-bearing mice, serum cytokine profiles
at 3 and 5 w p.i. in the RAW264.7 inoculation group
showed increased levels of M1-related cytokines
(MCP-1 and MIP-2 at 3 and 5 w p.i., and TNF-α at 5
w p.i. compared to 4T1 + RAW264.7 and 4T1) and
decreased levels of M2-related cytokines (BAFF at 3
and 5 w p.i., and G-CSF at 5 w p.i. compared to 4T1
+ RAW264.7 and 4T1; TGF-β1 at 3 and 5 w p.i. com-
pared to 4T1), reflecting the local M1−/M2-related
cytokine profile differences (Additional file 2: Figure S2).
In order to further investigate the immunological
profile of the primary tumors in both the 4T1 +
RAW264.7 and 4T1 inoculation group, immunohisto-
chemistry for CD45, CD163, Ly6G and CD8a was per-
formed on primary tumor sections at pre- (1 and 3 w
p.i.) and metastatic (5 w p.i.) time points (Fig. 6). Based
on the pan-immune cell marker CD45, the percentage
of immune cells increased and these cells invaded both
the 4T1 + RAW264.7 and 4T1 primary tumors over
time, but also remained partly in the surrounding
stroma (Fig. 6). At 1 w p.i., when tumor cells were still
in situ and did not yet invade the mammary fat pad,
immune cells were scarce. Only few CD163-positive
cells could be detected, which mainly comprise
tumor-recruited anti-inflammatory/M2 macrophages.
The CD163 stainings could not detect the intraduc-
tally inoculated RAW264.7 macrophages as these cells
are initially M1 polarized and also do not express
CD163 based on immunohistochemistry and western
blotting for CD163, respectively on paraffin slides and
in lysates of RAW264.7 inoculated mammary glands
(Additional file 3: Figure S3). At 3 w p.i. the CD163-posi-
tive tumor-recruited cells remained outside the tumor
area, but strongly increased in the 4T1 inoculation group
whereas in the 4T1 + RAW264.7 inoculation group a
similar CD163-positive staining was observed at 3 w
p.i. compared to 1 w p.i (Fig. 6). At 5 w p.i. the 4T1
+ RAW264.7 and 4T1 primary tumors showed similar
CD163 stainings, but the CD163-positive cells still
minimally invaded the tumor tissue. Western blotting
for CD163 corroborated the lower CD163 expression
at 3 w p.i. and similar CD163 expression at 5 w p.i in
Fig. 5 M1 to M2 polarization upon disease progression in 4T1 + RAW264.7, 4T1 and RAW264.7 intraductally inoculated mice. a, b Pro-inflammatory/
M1-related (IFN-γ, IL-1β, IL-6, MCP-1, MIP-2 and TNF-α) (a) and anti-inflammatory/M2-related cytokine levels (BAFF, G-CSF, IL-4, IL-10 and TGF-β1) (b) at
3 w p.i. in primary tumors/mammary glands from 4T1 + RAW264.7, 4T1 and RAW264.7 inoculated mice (n = 6 tumors/mammary glands for each
inoculation group). c, d Pro-inflammatory/M1-related (c) and anti-inflammatory/M2-related cytokine levels (d) at 5 w p.i. in primary tumors/mammary
glands from 4T1 + RAW264.7, 4T1 and RAW264.7 inoculated mice (4T1 + RAW264.7 inoculation group: n = 10 tumors; 4T1 inoculation group: n = 7
tumors; RAW264.7 inoculation group: n = 6 mammary glands). All data are presented as the means +/− SEM. NS: not significant, *: P < 0.05, **: P < 0.01,
***: P < 0.001
Steenbrugge et al. Journal of Experimental & Clinical Cancer Research  (2018) 37:191 Page 10 of 18
4T1 + RAW264.7 primary tumors compared to 4T1
primary tumors (Additional file 3: Figure S3B). Add-
itional immunohistochemistry for Ly6G and CD8a in
4T1 + RAW264.7 and 4T1 primary tumors also
showed few staining around the tumor-harboring
mammary ducts at 1 w p.i. However, at 3 and 5 w
p.i. the Ly6G and CD8a positivity increased and, in
marked contrast to CD163, were located within the
primary tumor area. Compared to the 4T1 primary
tumors, 4T1 + RAW264.7 primary tumors qualitatively
and quantitatively displayed increased staining for
Ly6G at 3 w p.i., whereas similar staining was de-
tected in both inoculation groups for CD8a at that
time point, and for Ly6G and CD8a stainings at 5 w
p.i (Fig. 6).
Extracellular matrix degradation and angiogenesis
were investigated at the protein level by measuring
the primary tumor lysate and serum levels of MMP-9
and VEGF in the 4T1 + RAW264.7 and the 4T1
inoculation group at 3 and 5 w p.i. Local MMP-9 and
VEGF levels in the primary tumor lysates increased as
tumor growth progressed from 3 to 5 w p.i. (Fig. 7a
and b). However, at 3 w p.i. the MMP-9 and VEGF
levels significantly decreased in the 4T1 + RAW264.7
compared to the 4T1 inoculation group, whereas this
difference was no longer seen at 5 w p.i. (Fig. 7a and
b). In accordance with the local and systemic cytokine
profiles, significantly decreased MMP-9 and VEGF
levels were detected in the RAW264.7 inoculated
mammary gland lysates compared to the 4T1 +
RAW264.7 and 4T1 inoculated counterparts at 3 and
5 w p.i. (Fig. 7a and b). Systemic MMP-9 levels also
progressively increased over time and were signifi-
cantly higher at both 3 and 5 w p.i. in the 4T1 +
RAW264.7 inoculation group compared to the 4T1
inoculation group and significantly lower in the
RAW264.7 inoculation group at 3 w p.i. compared to
the 4T1 + RAW264.7 inoculation group and at 5 w
Fig. 6 Immunohistochemistry of the tumor immune microenvironment in 4T1 + RAW264.7 versus 4T1 intraductally inoculated mice.
Immunohistochemistry for immune cell markers CD45 (pan-immune cell marker), CD163 (anti-inflammatory macrophage marker), Ly6G
(neutrophil marker) and CD8a (cytotoxic T-cell marker) was performed on paraffin sections of primary tumors at 1, 3 and 5 w p.i. from 4T1 +
RAW264.7 and 4T1 inoculated mice. The percentage of CD45-, CD163-, Ly6G- and CD8a-positive staining was quantified (n = 5 at each time point
and for each inoculation group). Dashed inserts and arrowheads highlight the few Ly6G- and CD8a-positive cells at 1 w p.i. Black scale bars =
50 μm; red scale bars = 20 μm. All data are presented as the means +/− SEM. NS: not significant, *: P < 0.05
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p.i. compared to both the 4T1 + RAW264.7 and 4T1
inoculation group (Fig. 7c). In contrast, VEGF serum
levels were close to the detection limit and moreover
did not increase between 3 and 5 w p.i. (Fig. 7d). Whereas
the systemic VEGF levels in the 4T1 + RAW264.7 and
4T1 inoculation group did not differ at 3 w p.i., at 5 w p.i.
the 4T1 + RAW264.7 inoculation group showed signifi-
cantly higher systemic VEGF levels compared to the 4T1
inoculation group (Fig. 7d). Systemic VEGF levels in the
RAW264.7 inoculation group were significantly lower
compared to the 4T1 + RAW264.7 and 4T1 inoculation
group at both 3 and 5 w p.i. (Fig. 7d).
Immunohistochemical stainings of 4T1 + RAW264.7
and 4T1 primary tumors with the endothelial cell
marker CD31 were indicative for an increase in vascular
growth over time. Upon quantification, significantly less
CD31 staining was observed in 4T1 + RAW264.7 com-
pared to 4T1 tumors upon invasion of tumor cells in the
mammary fat pad at 3 w p.i., mirroring the difference in
primary tumor VEGF response at that early time point
(Fig. 7e).
Onco-immunological responses and metastasis after
intraductal co-inoculation of 4T1 mammary tumor cells
with RAW264.7 macrophages correlate with local and
systemic CHI3L1 and LCN2 levels
CHI3L1 and LCN2 have previously been identified as
immune-related biomarkers for disease outcome in
breast cancer patients as well as for monitoring tumor
progression in the intraductal mouse model for TNBC
[6, 12–14]. Measurement of these two parameters in
4T1 + RAW264.7 and 4T1-only tumor-bearing mice
could therefore verify the observed differential breast
cancer burden between the two inoculation groups. Pre-
liminary in vitro tests showed that co-cultures of 4T1
tumor cells with RAW264.7 macrophages secreted
higher amounts of both CHI3L1 and LCN2 than either
4T1 or RAW264.7 mono-cultures (Fig. 8a and b).
CHI3L1 and LCN2 levels were subsequently measured
in primary tumor lysates and sera from 4T1 +
RAW264.7 and 4T1 inoculated mice and showed a pro-
gressive increase from 3 to 5 w p.i. (Fig. 8c-f ). Local
levels did not differ between 4T1 + RAW264.7 and 4T1
Fig. 7 Local and systemic MMP-9 and VEGF in 4T1 + RAW264.7, 4T1 and RAW264.7 intraductally inoculated mice. a, b Primary tumor/mammary
gland MMP-9 (a) and VEGF levels (b) at 3 and 5 w p.i. in 4T1 + RAW264.7, 4T1 and RAW264.7 inoculated mice (4T1 + RAW264.7 inoculation group:
n = 8 tumors at 3 w p.i. and n = 12 tumors at 5 w p.i.; 4T1 inoculation group: n = 8 tumors at 3 w p.i. and n = 6 tumors at 5 w p.i.; RAW264.7
inoculation group: n = 8 mammary glands at 3 w p.i. and n = 7 mammary glands at 5 w p.i.). c, d Serum MMP-9 (c) and VEGF levels (d) at 3 and 5
w p.i. in 4T1 + RAW264, 4T1 and RAW264.7 inoculated mice (4T1 + RAW264.7 and 4T1 inoculation group: n = 6 sera at 3 and 5 w p.i.; RAW264.7
inoculation group: n = 4 sera at 3 and 5 w p.i.). e CD31 immunohistochemistry on primary tumor sections from 4T1 + RAW264.7 and 4T1
inoculated mice at 1, 3 and 5 w p.i. (n = 5 at each time point and for each inoculation group). All scale bars = 50 μm. All data are presented as
the means +/− SEM. NS: not significant, *: P < 0.05, **: P < 0.01, ***: P < 0.001
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primary tumors, which is indicative for the similar pri-
mary tumor growth observed in both inoculation groups
(Fig. 8c and d). In marked contrast, systemic levels signifi-
cantly increased in 4T1 + RAW264.7 inoculated mice,
mirroring the increased CHI3L1 as well as LCN2 secretion
found in 4T1 + RAW264.7 co-cultures (Fig. 8e and f). Local
and systemic levels in the RAW264.7 inoculation group
were also lower than those in the 4T1 + RAW264.7 and
Fig. 8 CHI3L1 and LCN2 as immune-associated disease biomarkers in 4T1 + RAW264.7, 4T1 and RAW264.7 intraductally inoculated mice. a, b
CHI3L1 (a) and LCN2 (b) levels secreted in cell-free culture media of 24 h mono- and co-cultures of 4T1 mammary tumor cells and RAW264.7
macrophages (n = 3 for all culture conditions). c, d Primary tumor/mammary gland CHI3L1 (c) and LCN2 levels (d) at 3 and 5 w p.i. in 4T1 +
RAW264.7, 4T1 and RAW264.7 inoculated mice (4T1 + RAW264.7 inoculation group: n = 8 tumors at 3 w p.i. and n = 12 tumors at 5 w p.i.; 4T1
inoculation group: n = 8 tumors at 3 w p.i. and n = 6 tumors at 5 w p.i.; RAW264.7 inoculation group: n = 5 mammary glands at 3 and 5 w p.i.). e,
f Serum CHI3L1 (e) and LCN2 levels (f) at 3 and 5 w p.i. in 4T1 + RAW264.7, 4T1 and RAW264.7 inoculated mice (4T1 + RAW264.7 inoculation
group: n = 6 sera at 3 w p.i. and n = 7 sera at 5 w p.i.; 4T1 inoculation group: n = 6 sera at 3 and 5 w p.i.; RAW264.7 inoculation group: n = 4 sera
at 3 and 5 w p.i.). g, h Splenic CHI3L1 (g) and LCN2 levels (h) at 3 and 5 w p.i. in 4T1 + RAW264.7, 4T1 and RAW264.7 inoculated mice (n = 5 at
each time point and for each inoculation group). All data are presented as the means +/− SEM. NS: not significant, *: P < 0.05, **: P < 0.01,
***: P < 0.001
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4T1 counterparts at 5 w p.i., yet not at 3 w p.i. (Fig. 8c-f).
Additional measurements of the CHI3L1 and LCN2 levels
in spleen lysates from 4T1 + RAW264.7 and 4T1 inocu-
lated mice showed that in the two inoculation groups both
biomarkers increased over time with enhanced splenomeg-
aly, but remained low in the RAW264.7-only inoculated
mice. At 5 w p.i., when spleen sizes in the 4T1 +
RAW264.7 inoculation group were more severely increased
compared to their 4T1 counterparts, CHI3L1 and LCN2
levels were also significantly higher in the 4T1 + RAW264.7
spleen lysates than in the 4T1 spleen lysates (Fig. 8g and h).
Spleens from RAW264.7-only inoculated mice showed sig-
nificantly decreased CHI3L1 and LCN2 levels at 5 w p.i.
compared to both the 4T1 + RAW264.7 and 4T1 inocula-
tion group (Fig. 8g and h).
Discussion
Preclinical models remain essential for investigating
novel therapies to tackle cancer in humans. In the case
of breast cancer, such models are often established by
grafting mammary tumor cells in the mouse mammary
gland [20, 21]. Although the fat pad is the most fre-
quently inoculated site for these cells, we and others
have shown that the mammary ducts are a valuable al-
ternative inoculation site [6, 22–28]. When comparing
both inoculation sites, the fat pad model is representa-
tive for advanced invasive breast tumors whereas the
intraductal model more closely resembles human breast
cancer progression starting from DCIS before turning
into invasive and metastatic breast cancer. In a previous
study from our group, we observed that intraductally in-
oculated 4T1 tumor cells - which lack ER, PR and HER2
expression - show a slower primary tumor growth with
similar metastasis compared to their fat pad inoculated
counterparts [6]. Because of the lactating state of these
mice, tumor growth in the intraductal model is
accompanied by an involution process, resembling
pregnancy-associated breast cancer [29, 30]. Therefore,
the intraductal tumor model is also a relevant tool for
investigating this rarely studied, aggressive breast cancer
type. Furthermore, as immunocompetent mice were at
first used, this allowed the study of tumor-immune cell
interactions associated with ductal mammary tumor
progression.
Since macrophages are among the most important
regulators of the immune interactions in the breast
tumor microenvironment [8, 31], the current study fo-
cused on immune responses upon their intraductal
co-inoculation with 4T1 tumor cells. Either with or
without additional macrophages, the tumor cells grew
within the mammary ducts, invaded the ductal barrier
and progressed in the mammary fat pad from which they
spread towards the axillary lymph nodes and lungs in
the presence of a leukocytic reaction. In both intraductal
inoculation groups, primary tumors developed at a simi-
lar rate and displayed similar Ki67 tumor cell prolifera-
tion and hypoxia-associated CAIX expression. However,
based on stainings for the myoepithelial cell marker
cytokeratin 5 in primary tumors, the 4T1 cells disrupted
the ductal structures faster in the presence of additional
macrophages. Correlating with this enhanced ductal
breakthrough and tumor cell invasion, metastases in ax-
illary lymph nodes and lungs were increased in the mice
co-inoculated with additional macrophages.
Interestingly, in both inoculation groups, lung metasta-
ses showed characteristics of vessel co-option, i.e. the
metastasized tumor cells in the lung incorporated
pre-existing alveolar blood vessels rather than inducing
angiogenesis [32]. This non-angiogenic/alveolar histo-
pathological growth pattern of 4T1 lung metastases has
been reported with intravenous injections of 4T1 tumor
cells and correlated with poor response to anti-angiogenic
therapy [32]. In the current study, the tumor-bearing mice
inoculated with additional macrophages also suffered from
more severe splenomegaly, corroborating the reported
increased splenic erythropoiesis which compensated for
more advanced 4T1 tumor progression [33] and also
pointed to an augmented leukemoid reaction [6, 34].
Overall, our results indicate that additional macrophages
have a stimulatory effect on metastasis in the intraductal
model for TNBC.
Upon association of macrophages with a tumor, they
become TAM which stimulate breast cancer progression
by eliciting an immune response in favor to the growing
mammary tumor [7, 8]. This characteristic differentiates
them from the original homeostatic tissue macro-
phages that in marked contrast have the ability to
eliminate tumor cells through the establishment of a
pro-inflammatory environment and the presentation
of tumor antigens [7, 8]. These macrophages are clas-
sified as classically activated or M1-type macrophages.
Indeed, tumor cells can influence these innate immune ef-
fectors by educating them and change their activation
state towards M2 (i.e. alternatively activated macrophages)
in order to establish an anti-inflammatory microenviron-
ment that suppresses the host’s antitumor immune
response and ultimately causes tumor immune evasion
[7–9, 35, 36]. Our findings are highly indicative for a simi-
lar polarization of the RAW264.7 macrophage inoculum
by tumor cell signaling in the intraductal model for
TNBC. The decreased intracellular production of the
M1-related cytokine IL-12 and increased intracellular pro-
duction of the M2-related cytokine TGF-β1 by RAW264.7
macrophages co-cultured with 4T1 tumor cells compared
to mono-cultured RAW264.7 macrophages confirmed the
M1 to M2 polarization hypothesis, which was further
corroborated by secreted cytokine measurements in the
culture media. Turning to the in vivo situation,
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pre-metastatic 4T1 + RAW264.7 primary tumors showed
enhanced pro-inflammatory/M1-related and decreased
anti-inflammatory/M2-related cytokine profiles compared
to 4T1 primary tumors, whereas these differences between
both inoculation groups were no longer detectable upon
metastasis. It has been shown that 4T1 tumor cells com-
municate with RAW264.7 macrophages resulting in the
polarization of these immune cells and the subsequent
production of an immune suppressing tumor microenvir-
onment [37, 38]. In line with the education of the macro-
phages towards a M2 phenotype, the M1-related cytokine
profile was lower and the M2-related cytokine profile was
higher in primary tumors of 4T1 + RAW264.7 inoculated
mice at 3 and 5 w p.i. compared to RAW264.7 inoculated
mammary glands (i.e. no communication between 4T1
tumor cells and RAW264.7 macrophages). Based on intra-
ductal inoculations with saline (sham) and the determin-
ation of the induced immune cell influx and cytokine
profile as previously described by our group [39–42], it
can be suggested that the intraductal inoculation method
in se establishes a minimal local inflammation, which will
have contributed to a limited extent to the substantial
pro-inflammatory response observed in the primary tu-
mors in the current study. It might be a concern that mac-
rophages potentially create doublets with tumor cells and
could migrate to seed what looks like metastatic spread
[43, 44]. However, this scenario is unlikely to occur at
early disease stages when the RAW264.7 inoculum shows
characteristics of a M1 phenotype. Instead of doublet
formation, such M1/tumoricidal macrophages will
recognize the tumor cells as non-self and phagocytose
them, resulting in the loss of tumor cell-derived lumi-
nescent signal [45]. On the other hand, tumor cell/
macrophage doublet formation cannot be ruled out at
later stages when M2 macrophage polarization occurs and
RAW264.7 macrophages may lose their tumoricidal
activity. Nevertheless, our results suggest that macrophage
transfer and the proposed M1 to M2 macrophage
polarization facilitated the metastasis of intraductal 4T1
tumor cells, complementing a previous study relying on
mammary fat pad inoculations [46].
Immunohistochemical evaluation of pre- and post--
metastatic primary tumors showed an increase in the
recruitment of immune cells as a result of the cyto-
kine responses. More specifically, the infiltration of
CD8a-positive T-cells in both inoculation groups indi-
cates that the 4T1-based intraductal model for TNBC
gives rise to inflamed tumors [47], highlighting its
relevance for future screening of novel candidate im-
munotherapeutics. Furthermore, the decreased stain-
ing of the anti-inflammatory/M2 macrophage marker
CD163 and increased staining of the neutrophil
marker Ly6G at 3 w p.i. in 4T1 + RAW264.7 tumors
verified the observed respectively M2-related and
M1-related cytokine profiles in 4T1 + RAW264.7 inoc-
ulated mice prior to metastasis.
Macrophages also support breast cancer metastasis by
releasing matrix degrading MMPs such as MMP-9 and
angiogenic proteins such as VEGF. In the current study,
primary tumor MMP-9 and VEGF levels confirmed the
macrophage polarization from M1 to M2 and establish-
ment of an immune suppressing/tumor-supporting
microenvironment in 4T1 + RAW264.7 inoculated mice
as primary tumors from this inoculation group showed
lower MMP-9 and VEGF levels compared to the 4T1 in-
oculation group at pre-metastasis, but similar levels
upon metastasis. Our proposed M1 to M2 polarization
was emphasized by the lower levels of both mediators in
RAW264.7 inoculated mice and by CD31 immunohisto-
chemistry. Moreover, the strong increase in serum
MMP-9 and the moderate increase in VEGF serum
levels in the 4T1 + RAW264.7 compared to 4T1 inocu-
lated mice correlated with a significant increase in sys-
temic metastasis of the 4T1 primary tumors.
For verification of the mammary tumor disease pro-
gression either with or without additional macrophages,
two immune-related proteins CHI3L1 and LCN2, which
both have been identified as prognostic biomarkers in
breast cancer patients [12–14], were incorporated in the
current study. Indeed, we previously showed that
CHI3L1 and LCN2 levels increase progressively in pri-
mary tumors and sera of 4T1 intraductally inoculated
mice and confirmed the increase in tumor-associated
leukemoid responses as well as primary tumor growth
and systemic metastasis detected by in vivo and ex vivo
bioluminescence imaging [6]. Based on these observa-
tions, the in vitro observation of increased CHI3L1 and
LCN2 secretion in 4T1 + RAW264.7 co-cultures com-
pared to 4T1 and RAW264.7 mono-cultures provided a
preliminary indication of enhanced onco-immunological
responses due to the crosstalk between the tumor cells
and macrophages. In our in vivo experiments, similar
primary tumor levels but increased serum and spleen
CHI3L1 and LCN2 levels were measured in 4T1 +
RAW264.7 compared to 4T1 inoculated mice
corresponding to the similar primary tumor growth in
both inoculation groups, the increased metastasis and
enhanced leukemoid reaction in the additional macro-
phages inoculation group. The lower local and systemic
levels of both biomarker proteins in RAW264.7 inoculated
mice at 5 w p.i. further indicated the critical importance of
crosstalk with tumor cells and anti-inflammatory signaling
for the induction of CHI3L1 as well as LCN2. CHI3L1
and LCN2 are strongly produced by tumor cells and
TAM, and besides their immunomodulatory function both
biomarker proteins have been linked to several
tumor-promoting processes such as EMT, (lymph)angio-
genesis and matrix remodeling [48–54]. Moreover, the
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latter process is related to MMP-9 and it has been shown
that CHI3L1 induces MMP-9 production by macro-
phages, whereas LCN2 stabilizes this key matrix degrading
protein and regulates its activity [48, 52]. Accordingly, in
the current study the serum MMP-9 levels follow a similar
progressive trend as the serum CHI3L1 and LCN2 levels
with significantly increased levels prior to and upon me-
tastasis in the 4T1 + RAW264.7 compared to the
4T1-only inoculated mice.
Conclusion
Our results highlight the importance of macrophages in
metastatic breakthrough of intraductally inoculated 4T1
mammary tumor cells, but also the leukemoid reactions
that are associated with systemic spreading. More specif-
ically, we show here that the signaling between the tumor
cells and the macrophages in the mammary ducts results
in (1) increased ductal breakthrough and metastasis with
severe splenomegaly, (2) a M1 to M2 macrophage
polarization and establishment of an anti-inflammatory
microenvironment in support of metastasis, (3) aug-
mented systemic levels of immune-related biomarkers
CHI3L1 and LCN2 mirroring disease progression and
leukemoid responses. Based on these findings, future
study is warranted to explore tumor-associated macro-
phages and their crosstalk with tumor cells as potential
immunotherapeutic target for TNBC.
Additional files
Additional file 1: Figure S1. Immunohistochemistry for immune cells
and vascular endothelial cells in lung metastases of 4T1 + RAW264.7 versus
4T1 intraductally inoculated mice. Immunohistochemistry for immune cell
markers CD45 (pan-immune cell marker), CD163 (anti-inflammatory
macrophage marker), Ly6G (neutrophil marker) and CD8a (cytotoxic T-cell
marker) and the vascular endothelial cell marker CD31 was performed on
paraffin sections of lung metastases from 4T1 + RAW264.7 and 4T1
inoculated mice at 5 w p.i. to identify infiltrating immune cells and vascular
growth associated with 4T1 metastatic outgrowth in lungs. All scale bars =
50 μm. (TIF 22439 kb)
Additional file 2: Figure S2. M1−/M2-related cytokine levels in serum
of 4T1 + RAW264.7, 4T1 and RAW264.7 intraductally inoculated mice.
(A, B) Pro-inflammatory/M1-related (MCP-1 and MIP-2) (A) and anti-
inflammatory/M2-related cytokine levels (BAFF and TGF-β1) (B) at 3 w p.i.
in serum from 4T1 + RAW264.7, 4T1 and RAW264.7 inoculated mice (n = 5
sera for each inoculation group). (C, D) Pro-inflammatory/M1-related
(MCP-1, MIP-2 and TNF-α) (C) and anti-inflammatory/M2-related cytokine
levels (BAFF, G-CSF and TGF-β1) (D) at 5 w p.i. in serum from 4T1 +
RAW264.7, 4T1 and RAW264.7 inoculated mice (4T1 + RAW264.7 and 4T1
inoculation group: n = 5 sera; RAW264.7 inoculation group: n = 4 sera). All
data are presented as the means +/− SEM. NS: not significant, *: P < 0.05,
***: P < 0.001. (TIF 10349 kb)
Additional file 3 Figure S3. Immunohistochemistry of RAW264.7
inoculated mammary glands and western blot verification of M2-related/
anti-inflammatory CD163 levels in 4T1 + RAW264.7 versus 4T1 primary
tumors. (A) H&E histology and immunohistochemistry for the cell prolifer-
ation marker Ki67 and macrophage markers (CD45, F4/80 and CD163)
were performed on paraffin sections of RAW264.7 inoculated mammary
glands to verify the presence, growth and immune status of the intraduc-
tally inoculated RAW264.7 macrophages. All scale bars = 50 μm. (B)
Western blot for the anti-inflammatory CD163 levels and GAPDH loading
control levels in primary tumor lysates of 4T1 + RAW264.7 and 4T1 inocu-
lated mice at 3 and 5 w p.i. (n = 2 at each time point and for each inocu-
lation group), and in mammary gland lysates of RAW264.7 inoculated
mice at 5 w p.i. (n = 1) for verification of the CD163 immunohistochemis-
try results. The CD163 signals were quantified relative to the GAPDH sig-
nals. Data in panel B are presented as the means +/− SEM. NS: not
significant, *: P < 0.05. (TIF 16459 kb)
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